
Public health notice: Outbreak of Salmonella infections linked to various brands of salami and cacciatore products
This outbreak investigation is ongoing. The public health notice will be updated as the investigation evolves.
OTTAWA, ON, July 19, 2025 /CNW/ -
At a glance
Do not consume, use, sell, serve or distribute recalled salami and cacciatore products. For details on recalled product brand names and lot codes, please consult the Recalls and Safety Alerts website. Over 65 products have been recalled.
These products may have been used in prepared products like sandwiches or sold at deli counters.
Recalled food
Recall warnings have been issued for various salami and cacciatore products, including products from brands:
These products were distributed to:
These products may have been used and sold in prepared products like sandwiches or at deli counters. These warnings were triggered by findings from the food safety investigation.
For more information on the recalled products, including all product names, descriptions and lot codes, please consult the CFIA's notices on the Recalls and Safety Alerts website.
Rea brand Genoa Salami and Bona brand Genova Salami recalled due to Salmonella
Rea brand Soppressata Salami Sweet recalled due to Salmonella
Various brands of Salami and Cacciatore recalled due to Salmonella
How to protect your health
Salmonellosis is a foodborne bacterial illness that can affect anyone exposed to a contaminated food product, including the recalled product.
People who are infected with Salmonella bacteria can spread Salmonella to other people several days to several weeks after they have become infected, even if they don't have symptoms.
The following advice applies to individuals, as well as retailers, distributors and food service establishments such as specialty markets, delis, and cafes across Canada:
Most people who become ill from a Salmonella infection will recover fully after a few days without treatment, but it can also cause severe illness and hospitalization.
The Salmonella strain associated with this outbreak investigation is multi drug-resistant, which means it's resistant to certain antibiotics (streptomycin, kanamycin, ampicillin, and sulfisoxazole). Other antibiotics are available to treat illnesses associated with this outbreak strain, if antibiotic treatment is considered necessary.
Those at higher risk for serious illness include:
Symptoms
Salmonellosis has a wide range of symptoms. You may not get sick at all. However, if you do get sick, symptoms usually start within 6 to 72 hours after exposure.
You may experience:
Most symptoms end within 4 to 7 days.
While most people recover completely on their own, some people may have a more serious illness that:
Salmonellosis (Salmonella)
Food safety for vulnerable populations
Investigation summary
There are 87 laboratory-confirmed cases of Salmonella I 4,[5],12:i:- illness linked to this outbreak in:
The illness reported in British Columbia is related to travel to Alberta. People became sick between mid-April and late-June 2025. Of the cases reported, nine people have been hospitalized and there have been no deaths. Many people who became sick reported eating salami in prepared sandwiches or purchased from deli counters where the recalled products were served.
People who became sick are between 1 and over 100 years of age.
More recent illnesses may continue to be reported in the outbreak because there is a period between when a person becomes ill and when the illness is reported to public health officials. For this outbreak, the illness reporting period is between 11 and 45 days.
This outbreak may not be limited to the provinces with known illnesses. The recalled products were distributed to:
For more details on distribution please consult CFIA's notices on the Recalls and Safety Alerts website.
Related links
SOURCE Public Health Agency of Canada

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Increasing Fundings and Investments, Advanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Growth
The global cancer diagnostics market, valued at USD 23.84 billion in 2024, is forecasted to grow at an 11.5% CAGR, reaching USD 70.80 billion by 2034. Key drivers include rising cancer cases, early detection initiatives, and technological advances like AI and liquid biopsies. The robust market includes leaders like Roche, Thermo Fisher, and expanding regions such as North America. Cancer Diagnostics Market Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Diagnostics Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)" report has been added to global cancer diagnostics market was valued at USD 23.84 Billion in 2024, driven by the rising prevalence of cancer and increasing awareness and early detection initiatives across the globe. The market is anticipated to grow at a CAGR of 11.50% during the forecast period of 2025-2034, with the values likely to reach USD 70.80 Billion by 2034 . Cancer diagnostics involves identifying cancer early to improve treatment outcomes. It typically starts with a clinical evaluation, including physical exams and medical history reviews. Diagnostic tests like imaging (X-rays, CT scans, MRIs, PET scans) detect abnormalities, while blood tests identify cancer markers. Biopsies, where tissue samples are examined under a microscope, confirm malignancy and provide detailed information about the tumour. Advanced methods, such as molecular testing, identify genetic mutations to guide personalised treatments. Screening programmes, like mammograms and colonoscopies, help detect cancer in its early stages. Accurate diagnostics are essential for effective treatment planning and monitoring of disease Diagnostics Market Growth Drivers Rising Merger and Acquisition Activities to Accelerate Market GrowthIncreasing demand for specialised cancer diagnostics and expanding healthcare access in emerging regions are major drivers of growth in the market. For instance, in December 2024, Metropolis Healthcare Limited announced its acquisition of Core Diagnostics, based in Delhi NCR, for USD 29.62 million. This acquisition aims to strengthen Metropolis' cancer testing services and enhance its footprint across Northern and Eastern India. With Core Diagnostics' extensive oncology portfolio and its established network of 200 cities, this move will drive market expansion and enhance diagnostic capabilities. The deal is set to propel Metropolis into a leading position, stimulating market growth in the forecast period by offering advanced cancer diagnostics to a wider Fundings and Investments to Meet Rising Cancer Diagnostics Market DemandGrowing investments in innovative cancer therapies and advancements in radiotherapy are key drivers for the expanding market. For instance, in November 2024, ARC Innovation, part of Sheba Medical Center, secured USD 5.1 million in funding for Starget Pharma, a startup developing targeted radioligand therapies for precise cancer diagnosis and treatment. With funding from the Cancer Focus fund, supported by MD Anderson Cancer Center, Starget Pharma plans to conduct clinical trials on cancers such as sarcomas and melanoma. This breakthrough in cancer diagnostics and treatment will likely enhance the efficacy of therapies and offer new diagnostic tools, positioning this technology to significantly impact the global market in the forecast Diagnostics Market TrendsAdvanced Liquid Biopsy Technologies and Early Detection Methods Fuelling Market GrowthThe market is experiencing the rapid adoption of liquid biopsy technologies, which enable the detection of genetic mutations and biomarkers through blood samples. These non-invasive diagnostic tools are revolutionizing cancer detection by offering early diagnosis and real-time monitoring of treatment response. Liquid biopsy's increased accuracy and reduced patient discomfort are contributing to its growing popularity, particularly in precision oncology. As healthcare systems focus on improving early cancer detection, this technology's market demand is expected to rise significantly. Furthermore, advancements in molecular biology and bioinformatics will further boost its integration into clinical practice, expanding its market of Advanced Technologies to Impact the Cancer Diagnostics Market Value PositivelyArtificial intelligence (AI) and machine learning (ML) are playing a pivotal role in transforming the global cancer diagnostics market. AI-powered diagnostic tools enhance the accuracy of medical imaging, enabling early-stage cancer identification through pattern recognition and predictive analytics. These technologies not only improve diagnostic precision but also streamline workflow efficiencies, reduce human errors, and enhance treatment outcomes. With substantial investments being poured into AI in healthcare, the demand for AI-driven diagnostic solutions is growing. As the technology continues to evolve, its integration into cancer diagnostics will significantly increase market growth, driving future market value and development in the healthcare Partnerships Poised to Drive Cancer Diagnostics Market GrowthThe growing demand for precise and personalised cancer diagnostics is driving strategic collaborations in the field. For instance, in August 2024, Hitachi High-Tech Corporation and Gencurix, Inc. formed a partnership to develop cancer molecular diagnostics. By combining Hitachi's expertise in in vitro diagnostics and digital technologies with Gencurix's proficiency in biomarker discovery, the two companies aim to create advanced testing services. After a successful feasibility study, both companies are now set to commercialise these services in Japan. This collaboration will likely enhance the availability of molecular testing for cancer diagnosis, accelerating the growth of the global cancer diagnostics market by offering cutting-edge, more accurate diagnostic of Next-Generation Sequencing Technology to Increase Cancer Diagnostics Market SizeNext-generation sequencing (NGS) is a breakthrough technology that is rapidly transforming the global cancer diagnostics market. NGS offers high-throughput genomic analysis, enabling comprehensive testing of cancerous tissues to identify genetic mutations and potential therapeutic targets. This technology facilitates early detection of cancer, personalized treatment planning, and monitoring of therapeutic efficacy, contributing to better patient outcomes. The increasing availability of cost-effective NGS platforms and advancements in bioinformatics are driving its integration into clinical oncology practices. As a result, the NGS segment within the cancer diagnostics market is expected to experience substantial growth, adding significant value to the overall market. Key Questions Answered in the Cancer Diagnostics Market What was the global cancer diagnostics market value in 2024? What is the cancer diagnostics market forecast outlook for 2025-2034? What is market segmentation based on technology? How is the market segmented based on application? How is the market segmented based on clinical positioning? What are the major factors aiding the global cancer diagnostics market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the market's major drivers, opportunities, and restraints? What are the major cancer diagnostics market trends? Which technology will lead the market segment? Which application will lead the market segment? Which clinical positioning will lead the market segment? Who are the key players involved in the cancer diagnostics market? What is the patent landscape of the market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes: Report Attribute Details No. of Pages 400 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $23.84 Billion Forecasted Market Value (USD) by 2034 $70.8 Billion Compound Annual Growth Rate 11.5% Regions Covered Global Supplier Landscape Agilent Technologies, Inc. F. Hoffmann-La Roche AG Thermo Fisher Scientific, Inc. Becton, Dickinson and Company Danaher Corporation GE Healthcare Abbott Siemens Healthineers Bio-Rad Laboratories, Inc. Illumina, Inc. PerkinElmer Inc. QIAGEN Hologic, Inc. Myriad Genetics, Inc. Sysmex Corporation NeoGenomics Laboratories, Inc. Foundation Medicine Grail Guardant Tempus Delfi Diagnotics Exact Sciences Corporation Cancer Diagnostics Market SegmentationMarket Breakup by Technology Blood-based Diagnostics In Vitro Diagnostics Immunoassays Histopathology Others Molecular Diagnostics cfDNA Testing DNA Methylation Analysis Gene Sequencing Polymerase Chain Reaction (PCR) In Situ Hybridization Isothermal Nucleic Acid Amplification Technology (INAAT) Microarrays Spectrometry Others Non-blood-based Diagnostics Imaging CT MRI PET Others Biopsy Comparative Analysis Solid Liquid Others Others Market Breakup by Indication Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Cervical Cancer Blood Cancers (Leukemia and Lymphoma) Skin Cancer (Melanoma) Others Market Breakup by Clinical Positioning Screening Early Detection Treatment Guidance Treatment Response Assessment Market Breakup by Region North America Europe Asia Pacific Latin America Middle East and Africa For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Cancer Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Prestige Consumer Healthcare Inc. (PBH) Reinvents Retail Strategy for the Digital Age
We recently published Prestige Consumer Healthcare Inc. stands first on our list and is accelerating digital shift and boosting retail speed. Prestige Consumer Healthcare Inc. (NYSE:PBH) tops the list for being the most undervalued stocks. It is a leading marketer of over-the-counter (OTC) healthcare products, offering a wide range of personal wellness brands like Monistat, Summer's Eve, Dramamine, Clear Eyes, and DenTek. Headquartered in Tarrytown, New York, the company operates across the U.S., Canada, Australia, and select international markets. In 2025, a major development will be Prestige Consumer Healthcare Inc. (NYSE:PBH)'s digital transformation. By centralizing content management through platforms like Salsify, the company can now update product descriptions, images, and health information across retail partners like Walmart and Target within hours instead of weeks. This has improved product accuracy, boosted e-commerce visibility, and allowed the company to respond quickly to trends and regulations. 15 States with the Best Healthcare in the US The company's digital strategy also focuses on enhancing consumer engagement with lifestyle imagery and user-generated content, helping build stronger brand connections. The digital upgrade has made the corporation a more agile, tech-forward healthcare company ready to meet the growing demand for online health solutions. Additionally, the business remains committed to quality and consumer safety. The call center fields over 75,000 consumer inquiries annually, which helps inform product innovation. Rigorous testing, compliance checks, and third-party audits ensure high standards across its supply chain. By investing in digital tools and maintaining strong retailer relationships, Prestige Consumer Healthcare Inc. (NYSE:PBH) continues to build consumer trust and loyalty while leading in the evolving OTC healthcare market. While we acknowledge the potential of PBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. Sign in to access your portfolio


Medscape
3 hours ago
- Medscape
Key Drivers of High Costs in Head and Neck Cancer Care
TOPLINE: Advanced disease stage was the strongest predictor of high first-year healthcare costs in Canadian patients with head and neck cancer, a recent analysis found. Patients with stage IV disease had an almost ninefold greater likelihood for high healthcare costs than those with stage I disease. Combination treatments — especially surgery with adjuvant therapy — were also a major driver of high costs. METHODOLOGY: Patients with head and neck cancer experience considerable healthcare burdens due to aggressive and complex multimodal treatments, as well as long-term complications requiring rehabilitation and supportive care. Identifying predictors of high first-year costs can guide strategies to optimize resource use and improve patient outcomes. Researchers conducted a population-based retrospective cohort study using data from 13,795 Ontario, Canada, residents (mean age, 63.2 years; 25% women) who were diagnosed with head and neck cancer between January 2007 and October 2020. Researchers estimated total 1-year healthcare costs using a patient-level algorithm, with values adjusted to 2020 Canadian dollars (CAD), and identified predictors for high healthcare costs. Overall, 25% of patients were classified in the high-cost group (≥ 75th percentile; n = 3448), and 75% were classified in the low- or medium-cost group (< 75th percentile; n = 10,347). Patients in the high-cost vs low- or medium-cost groups were more likely to receive chemoradiotherapy (31.5% vs 19.0%), surgery with radiotherapy (20.0% vs 5.7%), or surgery with chemoradiotherapy (14.4% vs 4.1%), and were less likely to receive surgery alone (11.5% vs 27.4%) or radiotherapy alone (16.7% vs 26.1%). TAKEAWAY: Over 1 year, the biggest costs for patients in the high-cost group were inpatient stays (representing 41.0% of costs or CA$40,796 vs CA$5769 in the lower-cost group), outpatient visits (33.5% or $33,321 vs $16,953), physician services (12.5% or $12,436 vs $4959), complex and home care (8.7% or $8677 vs $1272), and drugs, devices, and lab tests (4.2% or $4208 vs $1576). Stage II (odds ratio [OR], 3.14), stage III (OR, 6.08), and stage IV (OR, 8.94) were associated with progressively greater odds of high healthcare costs than stage I disease. Combination treatment was associated with substantially greater odds of high costs than no treatment or palliative care (OR, 6.94 for surgery and radiotherapy; OR, 5.86 for surgery with chemoradiotherapy). Female sex (OR, 1.26) and older age (per each 10-year increase in age at diagnosis; OR, 1.07) were both associated with increased odds of high costs, as were diagnoses during the COVID pandemic (OR, 1.73) compared with prior years. IN PRACTICE: 'This cohort study found that more advanced disease stage and receiving multiple treatment modalities were the strongest predictors of high-cost care among patients diagnosed with head and neck cancer,' the authors of the study wrote. Potential solutions, they noted, include effective screening programs to promote earlier diagnosis, as well as interventions aimed at treatment de-escalation in appropriately selected patients. SOURCE: This study, led by Noémie Villemure-Poliquin, MD, MSc, Institute of Health Policy, Management, and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada, was published online in JAMA Otolaryngology-Head & Neck Surgery. LIMITATIONS: This study included only patients in Ontario, so findings may not be generalizable to other settings. Reliance on administrative data could have led to misclassification of disease severity and treatment types. Additionally, the analysis did not capture direct out-of-pocket costs. DISCLOSURES: This study received support through a grant from the Ontario Ministry of Health and the Ontario Ministry of Long-Term Care. One author reported receiving personal fees from EMD Serono and nonfinancial support from Elekta. Another author reported receiving personal fees from Cancer Care Ontario. No other disclosures were reported. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.